As of 4:00pm ET
| +0.02 / +2.17%|
AVEO Pharmaceuticals, Inc. operates as a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. Its proprietary human response platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. The company's product candidates include AV-203, ficlatuzumab, tivozanib and AV-380. AVEO Pharmaceuticals was founded by Ronald A. DePinho, Lynda Chin and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
|Michael P. Bailey||President, Chief Executive Officer & Director|
|Keith S. Ehrlich||Chief Financial Officer|
|Emile Farhan||Vice President-Technical Operations|
|Michael N. Needle||Chief Medical Officer|
|Karuna Rubin||Secretary, Head-Legal Affairs & Compliance|